Area of research
Infectious Diseases · Pulmonary and Respiratory Medicine
Research interest
Research interests include Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, Infectious Diseases and Tuberculosis, and Lung Cancer Diagnosis and Treatment.
Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.
Blood Transcriptomic and Clinical Biomarkers for Prediction of Tuberculosis Recurrence: A Multi-Country Validation Study
Modelling treatment response in tuberculosis early bactericidal activity trials
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond.
Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Target regimen profiles for tuberculosis treatment
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.
Accelerometer-Based Bed Occupancy Detection for Automatic, Non-Invasive Long-Term Cough Monitoring
Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects.
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study.
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg<sup>−1</sup>rifampicin
Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis.
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.
Clofazimine pharmacokinetics in patients with TB: dosing implications
Final Analysis of a Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis
Phase 2b Controlled Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878–1940
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
120. A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01E Vaccine Against Pulmonary Tuberculosis Disease in Adults With Latent Mycobacterium tuberculosis Infection
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Tuberculosis screening in immigrants from high‐prevalence countries: Interview first or chest radiograph first? A pro/con debate